LLY — All updates

20 entries loaded; 1 direction changes

Filter loaded records
Schwab NetworkPublished 2026-11-16
“Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings”
$LLYBullish
AI summary · Eli Lilly is somewhat defensive; continued obesity-drug launches, with Retatrutide/GLP-3 next, may make it a game-changer that eliminates the competition. The speaker says LLY, like Google, has 10 to 20% upside potential, and both can outperform for different reasons and in different scenarios.

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

Schwab NetworkPublished 2026-11-13
“PPI Mostly Cool, AI at "Crossroads" Amid NVDA CEO Search”
$LLYBullish
Schwab NetworkPublished 2026-11-12
“The Big 3: JNJ, LLY, AAPL”
$LLYBullish
AI summary · Eli Lilly is technically strong and the speaker expects a measured upward move: faster moving averages favor bulls, though it has not convincingly broken the 14.50 ceiling and RSI shows a bearish divergence. He prefers an options structure to capture upside while limiting downside, targeting 1560–1600 and an ideal 8–10% rise; the stock is expensive and hard for options, while healthcare should stay relatively strong into 2027.

Your next choice is also in the healthcare sector. We have Eli Lilly. I mean, perhaps Eli Lilly's chart is more technically clear. So , what is your outlook for Lilly? A similar view.

The momentum is definitely there from a technical standpoint. But again, I fundamentally believe that the healthcare sector will continue to demonstrate relative strength as we enter 2027.

It is an expensive stock. It is difficult to structure options positions on it due to the size of the stock and the cost of the options as well. However, I still believe there are opportunities, and that's why when I looked at the trading example today, the focus was on structuring a deal around options.

Therefore, to some extent, we identify downside risks with the ability to capture upward price movements.

Parkev Tatevosian, CFAPublished 2026-11-10
“My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell”
$LLYBullish
AI summary · Eli Lilly is a buy-and-hold-forever recommendation because its decades of serial successes, not just weight-loss treatments, make the current success non-fleeting; with the stock at $1,366 versus his $1,662 valuation, he owns shares and wants to add more.

What you see here is my valuation, and my discounted cash flow model for the first stock I'm going to mention that you can buy now and hold forever, which is Eli Lilly.

Eli Lilly is a pharmaceutical company with decades of experience in researching and developing treatments that generate billions of dollars in sales and profits. Currently, the company is benefiting from its recent success in weight loss treatments, but the company has a history of one success after another.

Everything MoneyPublished 2026-11-07
“Why The Nasdaq is Really Crashing in 2026 (Sell Now or Buy the Dip?)”
$LLYBearish
“Stock Market Warning: Tech Sells Off as Money Moves HERE!”
$LLYBullish
AI summary · Eli Lilly is expensive but just reached the buy zone today and, on a fresh plus base, offers another chance to buy; Lilly looks quite promising now because the medical trade is quite active.

This is an expensive stock. Its name is Eli Lilly and it just arrived at the Buy Zone today and gave you another chance. I believe they always give you another chance. And it's on a nice fresh plus base.

It went up and because the market was bad, it gave you another chance. So stocks like Lilly look quite promising now because the medical trade is quite active now.

T3 LivePublished 2026-11-03
“Scott Redler’s #630club - LIVE Premarket Stock Market Update”
$LLYBullish
AI summary · LLY has been doing absolutely fantastic and is technically acting well — it gave a move higher and held the eight-day; the speaker says to see whether the 1387 low holds.

So many freaking broken stuff. Yes, non tech looks okay. So, if you want to be in Eli Liy, Eli Liy has been doing absolutely fantastic. You know, if you want to take a pill to lose weight, I'm not judging you.

You could do that, too. I'm going to go on my son and my ice barrel and I'm going to sweat. But 7% of the world is taking pills to lose weight. Okay. Anyway, um stock technically has been acting well.

Gave you a move, held the eight day. Um go, you know, I have a friend who who's paying for every one of his kids college because he named his little daughter Lily. And uh Lily has had a tremendous run.

It's down 11 1397. Um what's this low here? 1387. So, um, see if that holds.

What they said to watch for
Verified InvestingPublished 2026-11-02
“Oil Drops Sharply Triggering Market Surge, Silver Bounces As AI Tech Trade Is Back On, Top Trades!”
$LLYBearish
AI summary · Eli Lilly is one of the speaker's favorite shorts right now. After new record highs while the AI trade collapsed, Friday's small doji could be a reversal signal and a decline may be starting. He watches for a drop to around 1290 to fill the gap at the pivot, a classic pullback setup.

One of my favorite short-selling deals right now, guys, is this one. Eli Lilly. Eli Lilly again, if you go to your monthly chart, you would swear and I would swear that this is an AI stock, but it is actually a pharmaceutical stock.

A major movement recently in artificial intelligence. Look at this upward movement here: while the AI trade was collapsing, Eli Lilly rose to new record highs. A small "Doji" candlestick was recorded on Friday, which could be a reversal signal.

Once again, there is a possibility of a decline beginning. I'll be watching for a drop to around 1290 here. Bridging this gap also represents the peak of this pivot point here, isn't it?

So again, bridge the gap there and then that pivot point there. A classic pullback opportunity seems likely in Eli Lilly's stock setup .

Meet KevinPublished 2026-10-31
“You've been WARNED.”
$LLYBullish
Rich HabitsPublished 2026-10-30
“Anthropic $2 Trillion IPO, Apple's "Crackgate," & Retatrutide Results”
$LLYBullish
Ale's World of StocksPublished 2026-10-29
“The REAL Reason BlackRock Bet $80B on Eli Lilly Stock 🚨”
$LLYBullish
Schwab NetworkPublished 2026-10-29
“Thursday's First Moves: FTNT Falls After Earnings, CAT Tumbles, LLY Rises”
$LLYBullish
AI summary · LLY's quarter was very strong and exceeded expectations, with adjusted EPS $7.48 vs $6.50 expected and revenue $24.4 billion vs $22.6 billion expected, and guidance raised. Its two main GLP-1 drugs both beat estimates and are about two-thirds of quarterly revenue, showing dependence; obesity pills have not arrived, a minor weakness offset by those drugs.

last but not least, there is some really great news for Eli Lilly, and the GLP -1 drug is still part of the story as well. Yes, they are winning the weight-loss battles for Eli Lilly, and these stocks are taking off again with gains of more than 7 % on the back of their quarterly results.

Very strong results that exceeded expectations; Earnings of $7.48 per share on an adjusted basis versus the $6.50 expected by the market, and revenue of $24.4 billion versus the $22.6 billion expected by the market.

So it was a quarter that exceeded expectations with the guidance raised.

Schwab NetworkPublished 2026-10-28
“Ghabour: Fed "Biggest Risk to Bull Market;" Bullish on MSFT, CRWD, LLY”
$LLYBullish
Meet KevinPublished 2026-10-20
“The NEXT Frontier: THESE 3 Stocks Boom”
$LLYBullish
AI summary · Eli Lilly is the least risky, most sensible pick: an acquisition machine he calls the S&P 500 of healthcare, using its $1.22 trillion market cap and capital to buy up successful startups and competitors. Its PEG of about 1.9 is under his preferred 2, and valuation stays reasonable despite strong performance.

This next option has a PEG ratio of around 1.9, which is a bit of a magic number as I prefer to be under two for some of these providers. This is the company here. It's Eli Lilly.

Eli Lilly is already a trillion-dollar company , but I call it the "S&P 500" of artificial intelligence. Because this meeting on Saturday could go disastrously for Moderna, and then the stock will fall back to $140, and you will have lost all your gains.

It could also go very well, and the stock could reach $300. This is your high-volatility option. Your least risky and most sensible option, in my opinion, is an option like Eli Lilly.

Meet KevinPublished 2026-10-20
“The Pain Returns... ALREADY AI, Fed, Iran, SpaceX”
$LLYBullish
Verified InvestingPublished 2026-10-14
“AI Stocks Bleed As Money Rotates Into Walmart, Lockheed And Lilly”
$LLYBearish
AI summary · LLY is up 4% today and rejecting an upward trendline from its April 30, 2026 low; the 1243-1244 area and 1249.45 pivot peak may favor a sell trade, while a break above could test the 1292.65 double top after a deep, healthy pullback; support is expected above 1133.95.

Walmart, Lockheed Martin, and even Eli Lilly are the most prosperous.

And finally, folks, Eli Lilly is having one of its best days in the market with a 4% gain today. What I'm watching here on the charts is this upward trend line from the low on April 30, 2026. This is exactly where the price is rejecting.

Ale's World of StocksPublished 2026-10-04
“5 Dividend GROWTH Stocks BlackRock is Buying Right Now! 🚨”
$LLYBullish
AI summary · LLY is a preferred dividend growth stock; high growth rates and low payout ratio make it attractive despite a sub-1% yield.

Okay, finally, this now brings us to the fifth and final purchase on the list. For this, we're actually going to be heading towards the healthcare sector, but we've already talked a lot about technology on this list.

In fact, there is a lot of technology in this company as well. So, not a very big change , but let's move on to this company, another big dividend growth option , namely pharmaceutical giant Eli Lilly ( trading symbol LLY), of which BlackRock acquired another $1.3 billion in the last quarter, bringing their total stake to more than $80 billion.

Rich HabitsPublished 2026-10-02
“Leaked Anthropic Financials, Oura Ring Delays IPO, & America.gov”
$LLYBullish
AI summary · LLY's Retatrotide drug (28% weight loss) drove a 25-28% profit on the speaker's LLY position; the drug is generating significant positive buzz.

You know that you will lose 20% of your weight using one of these GLP-1 drugs, from Eli Lilly, Novo Nordisk , or Regeneron.

Eli Lilly's retatrotide drug achieved a 28% weight loss, with patients reporting improvements in daily mobility.

Parkev Tatevosian, CFAPublished 2026-09-28
“3 Undervalued Healthcare Stocks Invstors Can Buy Right Now”
$LLYBullish
AI summary · LLY is undervalued (fair value $1,494 vs price $1,153) due to strong weight-loss drug momentum and FCF growth; expected to rise ~30% in 12-18 months.

We will move from a company with a market value of about one billion dollars to a company with a market value of more than one trillion dollars, which is Eli Lilly. I don't need to explain what Eli Lilly benefits from; the positive momentum is of course the weight loss treatments that have created a sales boom, which reminds me of the sales boom of artificial intelligence companies like Nvidia and Micron.

Ale's World of StocksPublished 2026-09-27
“Saudi Arabia is Secretly Loading Up on THESE 5 Stocks! 🚨”
$LLYBullish
AI summary · LLY is the best choice for growth given its dominant position in the weight loss/diabetes market and strong pipeline, though it lacks a high dividend yield.

moving on to the second purchase, we actually have to stay within the pharmaceutical sector for another name that has achieved, if you believe it, an even greater rise. It's kind of crazy.

This name is the recently trillion-dollar pharmaceutical giant, Eli Lilly, whose trading symbol is “LLY”, in which Saudi Arabia has nearly doubled its investments this quarter, pumping about $28 million into this center.

See older →
All updates for other tickers
Follow $LLY30-day free trial
Start trial